NCT04335383
Recruiting
Not Applicable
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial
University Hospital, Grenoble1 site in 1 country30 target enrollmentOctober 5, 2020
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pseudomonas Aeruginosa
- Sponsor
- University Hospital, Grenoble
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Isolation of recombinant human monoclonal antibodies against Pseudomonas aeruginosa
- Status
- Recruiting
- Last Updated
- 5 months ago
Overview
Brief Summary
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.
The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)
- •Patient with weight ≥ 32kg.
- •With a follow-up visit at Grenoble University Hospital with a blood sampling for its care
- •Having given its written no objection to participate in the prospective phase of this project
Exclusion Criteria
- •Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)
Outcomes
Primary Outcomes
Isolation of recombinant human monoclonal antibodies against Pseudomonas aeruginosa
Time Frame: 1 day
Detection of binding of recombinant antibodies to Pseudomonas aeruginosa target proteins by ELISA assay.
Secondary Outcomes
- Isolation of functional antibodies against Pseudomonas aeruginosa(1 day)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)Pseudomonas AeruginosaVentilation Acquired PneumoniaNCT01745796University Hospital, Grenoble77
Completed
Not Applicable
Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)Pseudomonas AeruginosaCOVID-19NCT06141837Central Hospital, Nancy, France51
Active, not recruiting
Phase 1
Pseudomonas Aeruginosa - Inhalation treatment, biomarkers and quality of lifeChronic pulmonary disease patients, except cystic fibrosis patients, with confirmed pulmonary infection by sputum sample positive for Pseudomonas Aeruginosa.MedDRA version: 18.1Level: LLTClassification code 10051190Term: Pneumonia Pseudomonas aeruginosaSystem Organ Class: 100000004862MedDRA version: 18.1Level: LLTClassification code 10050700Term: Chronic respiratory disease NOSSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2015-003662-87-DKAarhus University Hospital, Department of Respiratory Medicine
Active, not recruiting
Phase 1
Clinical study to assess two different Pseudomonas aeruginosa eradication protocols in patients with cystic ¿brosiscystic fibrosisMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2015-003881-96-ITAZIENDA OSPEDALIERO-UNIVERSITARIA MEYER112
Recruiting
Not Applicable
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa SepsisPseudomonas InfectionsPseudomonas SepticemiaPseudomonas; PneumoniaPseudomonal BacteraemiaPseudomonas Urinary Tract InfectionPseudomonas Gastrointestinal Tract InfectionSepsisSepsis, SevereCritically IllNCT03044223University of Ulm100